Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma

Published:2016-05 Issue:5 Volume:16 Page:e59-e64
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Ise Mikiko^ORCID,Matsubayashi Keiko,Tsujimura Hideki,Kumagai Kyoya

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference12 articles.

1. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;de Weers;J Immunol,2011

2. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma;Lin;Am J Clin Pathol,2004

3. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy;Bataille;Haematologica,2006

4. Immunophenotyping in multiple myeloma and related plasma cell disorders;Kumar;Best Pract Res Clin Haematol,2010

5. CD38-targeted immunochemotherapy in refractory multiple meyloma: a new horizon;Laubach;Clin Cancer Res,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different evasion strategies in multiple myeloma;Frontiers in Immunology;2024-02-23

2. Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma;Blood Advances;2023-11-30

3. Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab;American Journal of Clinical Pathology;2023-08-01

4. Primary Plasma Cell Leukemia Presenting Mainly with Negative CD38 Expression at Diagnosis: A Case Report with Literature Review;Journal of Applied Hematology;2023

5. Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept;International Journal of Molecular Sciences;2022-11-08